🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07770841
Recruiting Phase 3

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

NCT07770841 · tracked via the Priya Life Science USA tracker
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Started
2026-08-12
Last updated
2026-09-09

Condition(s) studied

OverweightObesity

Investigational drug(s) / intervention(s)

SemaglutidePlacebo

Semaglutide: Participants will receive semaglutide orally.

Placebo: Participants will receive placebo orally.

Study summary

The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Female or male (sex at birth). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) of 1. ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease. OR 2. ≥ 30.0 kg/m\^2. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records. * HbA1c ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.

Primary outcome measure(s)

Trial sites (62)

FacilityCityRegionStatus
Uni of Alabama at Birmingham Birmingham Alabama Recruiting
Headlands Research California, LLC Escondido California Recruiting
National Research Institute - Huntington Park Huntington Park California Recruiting
Los Angeles Institute for Metabolic Research Los Angeles California Recruiting
ERG Holding Company, LLC / Evolution Research Group, LLC Delray Beach Florida Recruiting
ERG Holding Company, LLC / Evolution Research Group, LLC Fort Myers Florida Recruiting
Jedidiah Clinical Research Tampa Florida Recruiting
East West Med Res Inst Honolulu Hawaii Recruiting
L-MARC Research Center Louisville Kentucky Recruiting
StudyMetrix Research LLC City of Saint Peters Missouri Recruiting
Jubilee Clinical Research, Inc. Las Vegas Nevada Recruiting
Corvallis Clinic PC Clinical Research Department Corvallis Oregon Recruiting
UPA Ctr Weight and Eating Dis Philadelphia Pennsylvania Not Yet Recruiting
Spartanburg Medical Research Spartanburg South Carolina Recruiting
Cedar Health Research Dallas Texas Recruiting
Selma Medical Associates Winchester Virginia Recruiting
Anima Research Center Alken Belgium Recruiting
Imelda Bonheiden Belgium Recruiting
UZ Brussel - Universitair Ziekenhuis Brussel Brussels Belgium Recruiting
Universitair Ziekenhuis Gent Ghent Belgium Recruiting
KORMONT Kluisbergen Belgium Recruiting
AIPSMC - DiMed EOOD Haskovo Bulgaria Recruiting
Medical Center Zdrave Lom EOOD Lom Bulgaria Recruiting
IPMC - Dr. Elizabeta Dimitrova Petrich Bulgaria Not Yet Recruiting
MHAT Hadzhi Dimitar OOD Sliven Bulgaria Recruiting
DCC Neoklinik EAD Sofia Bulgaria Recruiting
DCC 1 Velingrad EOOD Velingrad Bulgaria Recruiting
Aarhus Universitetshospital, Steno Diabetes Center Aarhus Aarhus N Denmark Recruiting
Gentofte Hospital - Center for Klinisk Metabolisk Forskning Hellerup Denmark Recruiting
Regionshospitalet Gødstrup, Hjertesygdomme Herning Denmark Recruiting
Hôpital Privé Saint Martin_Service de chirurgie digestive Caen France Recruiting
LES HOPITAUX DE CHARTRES_HOPITAL LOUIS PASTEUR_Service d'endocrinologie Le Coudray France Recruiting
Hôpital Privé La Louvière_Service de chirurgie Lille France Recruiting
CENTRE DE RECHERCHE CLINIQUE PORTES DU SUD_Service d'Endocrinologie-Diabétologie-Maladies Métaboliques Vénissieux France Recruiting
City Hospital Kliniki Monoprosopi I.K.E. Kalamata Greece Recruiting
Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit Marousi Greece Recruiting
Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department Peristeri Greece Recruiting
NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes Thessaloniki Greece Recruiting
Thermi Clinic S.A. - Diabetes and Internal Medicine Department Thessaloniki Greece Recruiting
Progress Clinical Research Amsterdam Amsterdam Netherlands Recruiting

+ 22 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07770841 on ClinicalTrials.gov ↗ ← All trials in the USA